The advent of next generation sequencing has led to identification of multiple novel molecular alterations in cancer.
Global TROP2 Antibody Market Clinical Trials Insight 2026 Report Findings:
- Research Methodology
- Global & Regional Market Analysis
- Global TROP2 Antibody Market Opportunity Assessment
- Market and Drug Sales Insight 2020 Till 2026
- Approved Drug In Market: 1 Drugs
- Future Market Assessment By Indication Till 2026
- Ongoing Clinical Trials Assessment by Status, Phase & Region
- Key Market Dynamics
- Competitor Landscape
Download Report
The advent of next generation sequencing has led to identification of multiple novel molecular alterations in cancer. Recently, researchers have identified trophoblast cell surface antigen 2 (Trop 2) which is a transmembrane glycoprotein encoded by the Tacstd2 gene. Originally, the expression of Trop 2 was described in trophoblasts (placenta) and fetal tissues. Since the discovery of Trop 2 in placenta, it is suggested that Trop 2 may play a key role in tumor development as being involved in several growth-stimulatory signaling pathways. In addition to this, the overexpression of Trop 2 was also considered valuable prognostic predictive biomarker for wide range of cancers including head and neck squamous cell carcinoma, gastric cancer, gallbladder cancer, cervical cancer, lung cancer, breast cancer, colon cancer, pancreatic cancer, ovarian carcinoma, and others.
Further, studies have shown that Trop 2 also have critical role in regulating several signaling molecules and also participates in signaling pathway which are linked with tumorigeneses, such as calcium signaling, β-catenin signaling, cyclin expression, and fibronectin adhesion. In cancer, the upregulation of Trop2 promotes the expression and activation of several downstream effectors, such as NF-kB, STAT1, and STAT3, through induction of the cyclin D1 and extracellular signal-regulated kinase (ERK)/mitogen-activated protein kinase (MAPK) kinase (MEK) signaling pathways, contributing to cell survival and growth. The co-expression of upstream and downstream tumor growth regulatory transcription network and partners in human tumors also suggests the role of Trop 2 in cancer development.
In last few years, antibody drug conjugates have entered the market which represents a new generation of highly potent anticancer drug. Antibody drug conjugates are the unique class of therapeutic agents which consists of three components including monoclonal antibody which targets the antigen, cytotoxic chemotherapeutic agent, and a chemical linker which bridges the two moieties together. The goal of antibody drug conjugate is to efficiently eliminate cells which express the target antigen and decrease systemic payload exposure.
Currently, Sacituzumab govitecan (Trodelvy) developed by Gilead Science is the only available TROP 2 inhibitor in the market which is indicated for the management of triple negative breast cancer and urothelial cancer. The novel drug comprises of humanized RS7 antibody and a cytotoxic payload, SN-38 which is a topoisomerase I–inhibiting drug that causes double-stranded DNA breaks that lead to apoptosis. Irinotecan is the prodrug of SN38 has shown anti-tumor activity but the complex pharmacology of SN-38 limits delivery of SN-38, which has a 100- to 1,000-fold higher potency than irinotecan. In comparison to this, the novel antibody drug conjugate, Trodelvy has demonstrated to deliver high levels of SN-38 to target cells with improved therapeutic index.
The entrance of Trodelvy in the market has shown encouraging response in the global market owing to its targeted nature. Apart from Trodelvy, several other Trop 2 targeting drugs are present in clinical pipeline which are expected to enter the market during the forthcoming years. The promising Trop 2 targeted therapies in clinical development include including DS-1062a, RN927C, BAT8003, SKB264, JS108 are present in clinical development. Datopotamab Deruxtecan developed by Daiichi Sankyo represents one of the most advanced stage inhibitor which is expected to enter the market in forthcoming years. Datopotamab deruxtecan is comprised of a humanized anti-TROP2 IgG13 monoclonal antibody, developed in collaboration with Sapporo Medical University, attached to a topoisomerase I inhibitor payload, an exatecan derivative, via a tetrapeptide-based cleavable linker.
Our report provides insight into the patent, price, dosage, and sale analysis of currently approved Trop 2 inhibitor. Further, the reports also give comprehensive analysis on the ongoing clinical trials in Trop 2 inhibitor market and other trends in the global market. Keeping in mind the various driver and challenges, the future outlook of Trop 2 inhibitors has also been analyzed in the report. Furthermore, the key players mentioned in the report are Arius Research, AstraZeneca, Gilead Sciences, Daiichi Sankyo, Janux Therapy, Pfizer, and Shanghai Junshi Biosciences.
Contact:
Neeraj Chawla
Research head
Kuick Research
+91-9810410366